Optical ventricular cardioversion by local optogenetic targeting and LED implantation in a cardiomyopathic rat model

Emile C.A. Nyns, Tianyi Jin, Magda S. Fontes, Titus van den Heuvel, Vincent Portero, Catilin Ramsey, Cindy I. Bart, Katja Zeppenfeld, Martin J. Schalij, Thomas J. van Brakel, Arti. A. Ramkisoensing, Guoqi Zhang, Rene. H. Poelma, Balazs Ördög, Antoine A.F. de Vries, and Daniël A. Pijnappels

1Laboratory of Experimental Cardiology, Department of Cardiology, Leiden University Medical Center (LUMC), Albinusdreef 2, 2300 RC, Leiden, The Netherlands; 2Department of Microelectronics, Delft University of Technology, Mekelweg 4, 2628 CD, Delft, The Netherlands; and 3Department of Cardiothoracic Surgery, LUMC, Albinusdreef 2, 2300 RC, Leiden, The Netherlands

Received 30 December 2020; editorial decision 3 September 2021; accepted 9 September 2021; online publish-ahead-of-print 16 September 2021

Time for primary review: 40 days.

Aims
Ventricular tachyarrhythmias (VTs) are common in the pathologically remodelled heart. These arrhythmias can be lethal, necessitating acute treatment like electrical cardioversion to restore normal rhythm. Recently, it has been proposed that cardioversion may also be realized via optically controlled generation of bioelectricity by the arrhythmic heart itself through optogenetics and therefore without the need of traumatizing high-voltage shocks. However, crucial mechanistic and translational aspects of this strategy have remained largely unaddressed. Therefore, we investigated optogenetic termination of VTs (i) in the pathologically remodelled heart using an (ii) implantable multi-LED device for (iii) in vivo closed-chest, local illumination.

Methods and results
In order to mimic a clinically relevant sequence of events, transverse aortic constriction (TAC) was applied to adult male Wistar rats before optogenetic modification. This modification took place 3 weeks later by intravenous delivery of adenovirus vectors encoding red-activatable channelrhodopsin or Citrine for control experiments. At 8–10 weeks after TAC, VTs were induced in vivo and in vitro, followed by programmed local illumination of the ventricular apex by a custom-made implanted multi-LED device. This resulted in effective and repetitive VT termination in the remodelled adult rat heart after optogenetic modification, leading to sustained restoration of sinus rhythm in the intact animal. Mechanistically, studies on the single cell and tissue level revealed collectively that, despite the cardiac remodelling, there were no significant differences in bioelectricity generation and subsequent transmembrane voltage responses between diseased and control animals, thereby providing insight into the observed robustness of optogenetic VT termination.

Conclusion
Our results show that implant-based optical cardioversion of VTs is feasible in the pathologically remodelled heart in vivo after local optogenetic targeting because of preserved optical control over bioelectricity generation. These findings add novel mechanistic and translational insight into optical ventricular cardioversion.

Keywords
Optogenetics • Ventricular tachycardias • Remodelling • In vivo

*Corresponding author. Tel: +31 71 5265330; fax: +31 71 526 68 09; E-mail: d.a.pijnappels@lumc.nl
†These authors contributed equally to the study.

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
1. Introduction

Biological excitation (i.e. generation of bioelectricity) plays a key role in the functioning of various organs, including the brain and heart. For the heart, disturbances in this process could lead to rhythm disorders including ventricular tachycardias (VTs), which are an important source of morbidity and sudden cardiac death worldwide. VTs most often occur in the setting of structural heart disease, i.e. in the pathologically remodelled heart. Current therapies for VTs include anti-arrhythmic drugs, catheter ablations, and implantable cardioverter defibrillators (ICDs). While drug treatment is often ineffective and hampered by side effects, catheter ablation can be effective for a selected subgroup of patients with monomorphic VTs and accessible substrates. However, catheter ablation may result in irreversible complications and generally comes with modest long-term efficacy. In contrast, high-voltage shocks from ICDs do terminate VTs in an effective manner and have been proven to reduce mortality in different cohorts of patients. These shocks are, however, not only very painful and can lead to depression and anxiety, but may also be delivered inappropriately and cause cardiac tissue damage. The development of novel therapies that decrease such adverse effects, while improving the termination success of hazardous VTs is hence of enduring relevance.

Optogenetics is a novel technology by which selected cells can be controlled in various ways and with an unprecedented degree of spatiotemporal control after being modified to express light-sensitive proteins. One class of such proteins are the channelrhodopsins, non-selective cation channels that open upon exposure to light of specific wavelengths. Illumination of channelrhodopsin-expressing cardiomyocytes results in sustained depolarization of the sarcolemma for the duration of illumination. Such optically controlled generation of bioelectricity has recently been applied in healthy rodents to pace the heart and to terminate pharmacologically induced arrhythmias, including VTs in ex vivo studies of isolated, non-remodelled hearts subjected to global and patterned illumination of the epicardium by an external light source. VTs, however, typically occur in pathologically remodelled hearts, while for their optogenetic termination to be realized in a clinically more relevant setting, an implantable light source for closed-chest, local illumination would be required.

In order to explore these translational requirements of optogenetic VT termination, we used adult rats selectively expressing the light-gated ion channel red-activatable channelrhodopsin (ReaChR) in cardiomyocytes. In these rats, the pathological structural and electrophysiological changes that are so prevalent among VT patients were mimicked using transverse aortic constriction (TAC)-induced chronic pressure overload resulting in a cardiomyopathic phenotype characterized by myocardial hypertrophy and fibrosis. Moreover, we refined the illumination method by applying a custom-made, implantable LED device for local illumination of the apex of the heart to enable experiments in the fully closed-chest in vivo setting.

2. Methods

A detailed description of all methods and materials is provided in the Supplementary material online.

2.1 Study design

All animal experiments were approved by Animal Experiments Committee of the Leiden University Medical Center, the Netherlands (AVD1160020172929) and performed in accordance with the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes. The experimental design of the study is illustrated in Figure 1A. At indicated timepoints post-TAC or sham surgery, male Wistar rats (Crl: WI[WU]; Charles River Laboratories, Cologne, Germany) were subjected to electro- and echocardiographic measurements and received adeno-associated virus vectors (AAVs) (2 × 10^13 genome copies) coding for ReaChR, or Citrine as negative control protein. Male rats were used because their hearts are larger than those of age-matched female rats, which facilitated the induction of sustained VTs. The feasibility and efficacy of optical VT termination were assessed by ex vivo and in vivo apical illumination of the heart. To this purpose, a miniaturized device was constructed that consisted of four LEDs producing 567 nm (lime) or 617 nm (red) light (LUXEON Z Color line LXZ1, Lumileds, San Jose, CA), a support frame, and a transparent layer of UV curable optical adhesive (NOA63, Norland Products, Cranbury, NJ). Electrophysiological, histological, and optical studies were performed at the cellular and/or tissue level for safety assessment and in-depth mechanistic insight.

2.2 TAC surgery and intravenous AAVV injections

Rats were anaesthetized using 2–3% isoflurane vapour in O₂ at 0.8 L/min. Baseline ECG data were collected using an 8-channel PowerLab data acquisition device and recorded and analysed using LabChart Pro software version 7 (both from ADInstruments, Oxford, UK). The rats were 9–10 weeks old when they underwent TAC or sham surgery. Adequate anaesthesia was confirmed by the absence of the pedal reflex. Pressure overload was induced via TAC surgery as previously described. Briefly, the aorta was exposed via the second left intercostal space. A 4–0 silk suture was placed around the aorta between the brachiocephalic trunk and left common carotid artery. A spacer made from a 21 G hypodermic needle was placed next to the transverse aorta. To constrict the aorta, the suture was tied around the aorta and spacer before removing the spacer. Animals assigned to receive sham surgery underwent the same procedure, except that no suture was tied around the aorta. Adequate analgesia was provided before and after surgery by subcutaneous injections of buprenorphine hydrochloride (0.05 mg/kg). In the first 3 days following surgery, subcutaneous injections were administered twice a day in case of signs of discomfort. Three weeks after successful TAC or sham surgery, 2 × 10^13 genome copies of AAV2/9.GgTmnt2.ReaChR.Citrine.WH/PRESV40pA or AAV2/9.45.GgTmnt2.Citrine.WH/PRESV40pA diluted with phosphate-buffered saline to a final volume of 700 μL were slowly injected into the tail vein using a 25 G needle (Becton Dickinson, Breda, the Netherlands). Rapamycin (3 mg/kg; LC Laboratories, Woburn, MA) was administered every other day by intraperitoneal injections for 4 weeks. Rats were euthanized by removal of the heart following analgesia with buprenorphine hydrochloride and anesthesia with isoflurane as described above.

2.3 VT induction and use of multi-LED implant for VT termination in vivo

In Week 8–10 post-surgery, animals were anaesthetized as described above and the heart was exposed. VTs were induced by S152 programmed electrical stimulation or electrical burst pacing (cycle length 20–30 ms) using a STG4002 stimulus generator with MC Stimulus II software (Multichannel Systems, Reutlingen, Germany). As most self-limited VTs lasted <5 s, optical VT termination was attempted when VTs lasted longer than 5 s. The LED device used in the apical illumination experiments was attached to the apex using two drops of histacyl tissue glue (B. Braun, Melsungen, Germany). The optical termination protocol consisted of up to three 500 ms pulses with a...
500 ms interval. The termination protocol was stopped once the VT was terminated. VTs were considered to be optogenetically terminated if the arrhythmia stopped within 1 s following the end of the last light pulse. ECG recordings were acquired and analysed as described earlier.12

2.4 Statistics
Statistical analyses were performed using SPSS Statistics v23.0 (IBM, Armonk, NY). The Mann–Whitney U test was performed for the comparison of illumination and control groups. Other data were compared by using the two-sided Student’s t-test for unpaired data and the two-sided paired Student’s t-test for paired data. Data were expressed as means ± standard deviation or, for arrhythmia termination efficiencies, current densities, and membrane potentials as means ± standard error of the mean (SEM). The whole-cell patch clamp measurements are expressed as the means of the raw data; the sharp electrode data are expressed as the means of the means. Differences were considered statistically significant at $P < 0.05$.

3. Results
3.1 Characterization of the TAC model
Evaluation of cardiac contractile and electrophysiological function by echo- and electrocardiography 8–10 weeks after TAC or sham surgery
showed a significantly impaired myocardial fractional shortening (32.5 ± 4.9 vs. 41.8 ± 1.9%, \( P < 0.001 \)) and prolonged QRS duration (20.5 ± 4.5 vs. 15.8 ± 1.7 ms, \( P = 0.015 \)) in rats 10 weeks after TAC (\( n = 10 \)). The QRS duration did not significantly change in rats that underwent sham surgery (17.0 ± 1.3 vs. 17.3 ± 0.9 ms, \( P = 0.449 \) at baseline vs. Week 10, \( n = 10 \)). A significant yet functional irrelevant change was present with regard to the fractional shortening in the sham group (41.1 ± 1.3 vs. 41.8 ± 1.6%, \( P = 0.002 \) at baseline vs. Week 10) (Figure 1A–D).

Electrical remodelling in TAC rats was demonstrated by significant prolongation of sharp electrode-derived action potential duration at 80% repolarization (APD80) (97.5 ms vs. 52.3 ms, \( P = 0.001 \), number of hearts per group: 5, median number of impalements per heart: 2) and ECG-derived corrected QT interval (140 ± 17 vs. 117 ± 5 ms, \( P = 0.001 \), \( n = 10 \)) when compared to sham-operated animals.

Left ventricular (LV) hypertrophy in TAC rats was demonstrated by a significantly increased LV wall thickness, measured histologically in the mid-papillary short-axis plane (3.03 ± 0.28 vs. 2.40 ± 0.22 mm in sham-operated animals, \( P = 0.001 \), \( n = 7 \)) (Figure 1E), which was in agreement with a significant increased heart-to-body weight ratio (5.3 ± 1.3 mg/g in TAC vs. 3.5 ± 0.2 mg/g in sham-operated rats, \( P < 0.001 \), \( n = 10 \)) (Figure 1F). Further evidence of ventricular remodelling was obtained by histochemical assessment of fibrosis, which demonstrated enhanced deposition of collagen in ventricular myocardium of TAC rats compared to sham-operated controls (5.0 ± 1.6% vs. 1.9 ± 1.6%, \( P < 0.001 \), \( n = 10 \)) (Figure 1G). In addition, the average cell size represented by the whole-cell capacitance of ventricular cardiomyocytes was significantly increased in cells isolated from TAC animals compared to those of sham-operated rats (250 ± 14.3 pF vs. 175 ± 26.3 pF, respectively, \( P < 0.05 \), \( n = 7 \)), indicating the presence of structural remodelling in TAC hearts at the cellular level.

Intravenous administration of purified ReaChR-encoding AAVV particles (Supplementary material online, Figure S1A and B) resulted in similar transduction rates of ventricular cardiomyocytes in TAC and sham-operated rats (71 ± 8% vs. 70 ± 10%, respectively, \( P = 0.726 \), \( n = 10 \)). Thus, efficient AAVV-mediated optogenetic transgene delivery and expression remained feasible in hearts undergoing pathophysiological changes due to TAC-induced pressure overload (Figure 1H).

### 3.2 Electrophysiological characterization of ReaChR photocurrents and membrane response

Whole-cell patch clamp measurements of ReaChR-expressing ventricular cardiomyocytes showed strong depolarizing photocurrents upon 470 nm illumination (1 s, 10 mW/mm²) for both TAC and sham-operated rats (Figure 2A). This inward current was observed at a wide range of membrane potentials negative to the reversal potential of the ReaChR current (−10 mV) in both groups (Figure 2B). Kinetic parameters of the ReaChR current, including time-to-peak and time constant of inactivation and closing were not significantly different between TAC and sham animal-derived cardiomyocytes (Figure 2C–E). Illumination at 470 nm produced robust peak (−2.6 ± 0.5 nA vs. −2.5 ± 0.6 nA, \( P = 0.9405 \)) and plateau (−1.4 ± 0.2 nA vs. −1.3 ± 0.3 nA, \( P = 0.9479 \)) photocurrent amplitudes in both the TAC (\( n = 8 \) cells isolated from five hearts) and sham group (\( n = 7 \) cardiomyocytes from two hearts), respectively (Figure 2F and G). In addition, 470 nm illumination led to sustained plasma membrane depolarization during the entire duration of illumination (Figure 2H) from an average resting membrane potential (\( V_{\text{rest}} \)) of −74.2 ± 0.8 mV and −77.7 ± 3.5 to plateau potentials (\( V_{\text{plateau}} \)) of −15.4 ± 7 mV and −13.5 ± 8.7 mV in cardiomyocytes of TAC (\( n = 7 \) cells obtained from four hearts) and sham-operated (\( n = 5 \) cells from two hearts) animals, respectively. There were no statistical differences between the two experimental groups (Figure 2I and J), which demonstrates that ReaChR-mediated depolarization of the sarcolemma remains effective in a pathophysiological cardiac substrate.

### 3.3 Development of a custom-made LED device for apical implantation

Since the penetration depth of visible light increases with its wavelength and ReaChR has a broad action spectrum that extends into the red portion of the visual spectrum,\(^ {14} \) we next performed additional whole-cell patch clamp experiments, sharp electrode measurements, and computational simulations evaluating 470, 567, and 617 nm light in order to find out which wavelengths are the most suited for in vivo optogenetic VT termination. Peak photocurrent amplitudes were on average 54.6 ± 8.3% higher for 567 nm and 40 ± 31% higher for 617 nm light pulses when compared to 470 nm light pulses (1 mW/mm²) (\( n = 6 \) cardiomyocytes from three hearts, \( P = 0.0006 \) and \( P = 0.0054 \), respectively), whereas the plateau photocurrent amplitudes were very similar (\( P > 0.05 \)) across these wavelengths (Figure 3A and B). In addition, no significant differences were observed in membrane plateau potentials upon illumination with 500 ms light pulses (1 mW/mm²) of 470, 567 or 617 nm (\( n = 6 \) cardiomyocytes from three hearts, \( P > 0.05 \)) (Figure 3C). Sharp electrode measurements on ReaChR-expressing apical tissue samples demonstrated strong and sustained membrane depolarization upon illumination with 470, 567, and 617 nm light pulses of 500 ms and with intensities of ≥0.25 mW/mm² (Figure 3D and Supplementary material online, Figure S2A). Importantly, tissue samples were rendered unexcitable for the entire duration of illumination as demonstrated by loss of capture in response to electrical pacing during illumination (from 0.1 mW/mm² for 470 and 567 nm light and from 0.25 mW/mm² for 617 nm light) (Supplementary material online, Figure S2B). However, computer simulations predicted that 567 and 617 nm were more effective in penetrating blood-perfused ventricular myocardium, thus potentially allowing excitation of a substantially larger ventricular mass than can be excited with light of 470 nm (Figure 3E). Since these experiments demonstrated that at an intensity of ≥0.25 mW/mm², 567 and 617 nm light produced similar membrane potential responses but larger peak photocurrents and improved tissue penetration in comparison to 470 nm light, the 567 nm and 617 nm wavelengths were used for the whole heart experiments. To this end, we designed custom-made 567 and 617 nm multi-LED devices small enough for direct epicardial application in vivo. These devices consisted of a central LED surrounded by three equally spaced LEDs with the same specifications (Figure 4A and B) and were designed to be attached to the cardiac apex (Figure 4C and D) because of its favourable epicardial surface to ventricular mass ratio and central location in relation to both ventricles and septum. In addition, the apex might be an interesting target for optogenetic VT termination since there is evidence that it attracts scroll waves (i.e. re-entrant activity sustaining the arrhythmia) because of its geometrical curvature combined with high levels of anisotropy.\(^ {15} \) Sustained depolarization of the apex might therefore result in highly effective optogenetic VT termination by scroll wave filament destabilization and extinction.

To evaluate the thermal responses of the 567 and 617 nm LED devices when activated for three consecutive 500 ms light pulses with a 500 ms interval, temperature measurements were performed ex vivo in an incubator set at 37°C. The maximum temperature of the devices,
measured on the ventricle-facing surface directly above the PDMS-insulated LED chip, was 36.8°C (range 36.7–37.0°C) before illumination and briefly peaked to an average absolute maximum temperature of 41.1 ± 0.2°C for 567 nm (15 mW/mm²) and 38.1 ± 0.1°C for 617 nm (10 mW/mm²) light after the third light pulse (Supplementary material online, Figure S3A and B). For the 567 nm LED device, the measured time

**Figure 2** Electrophysiological characterization of ReaChR photocurrents and membrane response in ventricular cardiomyocytes derived from TAC and sham-operated animals.

In all voltage- and current-clamp experiments, ReaChR was activated by 470-nm light (1 s, 10 mW/mm²). (A) Representative whole-cell voltage clamp recording of ReaChR photocurrents from an isolated TAC cardiomyocyte. The membrane potential was clamped at -90 mV. I_{peak}: maximal current amplitude, I_{plateau}: current amplitude at the end of the illumination period, time-to-peak: the length of the time interval between the beginning of illumination and the appearance of I_{peak}, T_{inact}: half-decay time of current decay from I_{peak} to I_{plateau}, T_{off}: half-decay time of current decay from I_{plateau} to zero current. (B) ReaChR I_{plateau} amplitudes observed at a range of holding potentials between -110 and 50 mV. (C) Time-to-peak values of ReaChR current representing activation kinetics of ReaChR. (D) T_{inact} values of ReaChR current representing ReaChR inactivation kinetics. (E) T_{off} time constant representing ReaChR closing kinetics. (F and G) ReaChR I_{peak} and I_{plateau} amplitudes measured at -90 mV holding potentials. (H) Representative membrane potential response to 470 nm illumination (blue bar) recorded under current-clamp conditions in a cardiomyocyte isolated from a TAC animal. (I) Resting membrane potentials (V_{rest}) observed before illumination. (J) Plateau potentials (V_{plateau}) measured at the end of the 1 s light pulse. Each dot represents the results of an individual cell. For (C–H), n = 8 cells from four hearts in the TAC group and n = 7 cells from two hearts in the sham group. For (I) and (J), n = 7 cells from four hearts in the TAC group and n = 5 cells from two hearts in the sham group. Numerical data are represented as mean ± SEM, all P-values were calculated by the Student’s t-test.
between 40.0 and 41.1°C was <2 s (Supplementary material online, Figure S3A). Importantly, as a safety assessment, optical voltage recordings of the apex after repetitive LED activation in vivo and ex vivo demonstrated wave front propagation over the entire surface of the apex without regional conduction disturbances, which indicates that attachment and frequent activation of the LED device did not lead to detectable sustained electrophysiological disturbances (Figure 4E). This finding is in line with the concept of CEM43 (i.e. cumulative equivalent minutes at 43°C), a standardized thermal dose concept that assesses the impact of different transient heat exposure scenarios on the viability of tissue and cells.16 In the context of cardiac ablation therapy, it has been proposed that the critical CEM43 for myocardium is 128 min,17 well above the CEM43 of <0.1 min in this study.

3.4 Optogenetic VT termination of the remodelled heart by the LED implant ex vivo

Each LED device was first evaluated ex vivo in isolated TAC hearts using a Langendorff apparatus. After induction of sustained (>10 s) VTs by electrical burst pacing, the LED device was activated for 500 ms up to three times (interval of 500ms) with the LED at the tip of the apex or with all four LEDs covering 1.9 and 7.6 mm² of the apical epicardium, respectively. VT termination was feasible with light pulses of 470 nm, the single dots represent averaged values. (C) ReaChR plateau potentials (V_plateau) measured at the end of a 500 ms light pulse (1 mW/mm²) for 470, 567, and 617 nm light. Each dot represents the results of an individual cell (n=6 cells from four hearts). (D) Representative sharp electrode measurements of a ReaChR-expressing ventricular tissue sample from a TAC rat showing sustained depolarization illumination for 500 ms with blue (λ=470 nm), lime (λ=567 nm), or red (λ=617 nm) light of various intensities. All recordings are from the same ventricular spot. (E) Computational simulations of propagation of 470, 567, and 617 nm light through rat myocardium.

### Figure 3
Whole-cell patch clamp and sharp electrode measurements of ReaChR photocurrents and membrane potential responses, and computational light penetration simulations at different excitation wavelengths.

(A and B) Relative ReaChR I_peak (A) and I_plateau (B) amplitudes measured at -90 mV holding potentials upon illumination with 567 or 617 nm light compared to 470 nm light as the index (500 ms, 1 mW/mm²). Each dot represents the paired results of an individual cell (n=6 cells from four hearts). For the light pulses of 470 nm, the single dots represent averaged values. (C) ReaChR plateau potentials (V_plateau) measured at the end of a 500 ms light pulse (1 mW/mm²) for 470, 567, and 617 nm light. Each dot represents the results of an individual cell (n=6 cells from four hearts). (D) Representative sharp electrode measurements of a ReaChR-expressing ventricular tissue sample from a TAC rat showing sustained depolarization illumination for 500 ms with blue (λ=470 nm), lime (λ=567 nm), or red (λ=617 nm) light of various intensities. All recordings are from the same ventricular spot. (E) Computational simulations of propagation of 470, 567, and 617 nm light through rat myocardium.
3.5 Optogenetic VT termination of the remodelled heart by the LED implant in vivo

Next, we evaluated the feasibility and efficacy of optogenetic VT termination by the LED implant in vivo. After introduction via the left 6th intercostal space, the LED device was implanted at the apex of anaesthetized and mechanically ventilated TAC rats (Figure 6A). Although the thoracic wall could be completely closed with a fully functional LED device in situ (Figure 6A and B), the optogenetic VT termination experiments were performed with an open incision to facilitate convenient VT induction by programmed electrical stimulation. Following induction of sustained VTs, termination could be realized by one, two, and three 500 ms pulses (Figure 6C–F and Supplementary material online, Figure S4A). The mean successful optogenetic VT termination rate after three consecutive 500 ms light pulses (567 nm: 15 mW/mm²; 617 nm: 10 mW/mm²) was 95% (SEM 5%) for 567 nm light (corresponding to 20 VT episodes in four ReaChR-expressing TAC rats) and 86.7% (SEM 6.7%) for 617 nm light (corresponding to 15 VT episodes in three ReaChR-expressing TAC rats). In Citrine-expressing TAC rats, very few VT episodes terminated under the same illumination conditions (Figure 6E and Supplementary material online, Figure S4B), resulting in termination rates of 15% (SEM 5%) (P = 0.015) and 13.3% (SEM 6.7%) (P = 0.043) for light of 567 and 617 nm, respectively (Figure 6F). The average RR interval 2 s before VT induction and 2 s after VT termination showed no statistically significant differences for 567 nm (0.252 ± 0.046 vs. 0.260 ± 0.041 s, n = 18 individual measurements from four rats; P = 0.240) or 617 nm light (0.208 ± 0.017 vs. 0.211 ± 0.022 s, n = 13 individual measurements from three rats; p = 0.514) (Figure 6G), i.e. normal rhythm was instantly restored following optical cardioversion.

4. Discussion

Our results demonstrate successful optogenetic VT termination in the structurally and electrically remodelled rat heart in vivo by apical illumination using an implanted light source. These results are an important step forward in the clinical development of cardiac optogenetics for ventricular arrhythmia management since the large majority of VT patients exhibit structural heart disease and in situ light delivery is an absolute prerequisite for clinical implementation. Previous studies have reported successful optogenetic termination of pharmacologically induced ventricular arrhythmias in explanted, Langendorff-perfused hearts from healthy rodents. In order to mimic structural heart disease characteristics of VT patients, a TAC model was used to induce LV hypertrophy, myocardial fibrosis, reduced cardiac function, and ventricular conduction abnormalities; factors that predispose the heart to potentially life-threatening arrhythmias. Importantly, we now show that these TAC-induced pathological changes do not impair the transmembrane currents and plateau potentials of ventricular cardiomyocytes and ventricular tissue upon optogenetic modification and subsequent illumination. This substantiated that the prominent anti-arrhythmic mode-of-action of cardiac optogenetics, namely depolarizing photocurrent-induced inhibition of excitation, remains effective under such conditions as demonstrated in our whole heart experiments. In recent studies, Cheng et al. found that optogenetic termination of VTs is also feasible during acute ischaemia and chemically induced fibrosis after AAVV-mediated channelrhodopsin gene transfer to the hearts of healthy juvenile rats and channelrhodopsin activation by an
external blue light source. The use of custom-made implantable light sources emitting red-shifted light allowed us to demonstrate and explain that optical VT termination is feasible in blood-perfused, chronically remodelled hearts in vivo. Furthermore, the finding that VT termination can be achieved by illumination of a relatively small area is promising from a clinical perspective. While this study demonstrated that illumination of larger surface areas increased VT termination rates, it is remarkable that epicardial illumination of 24 mm² of the cardiac apex still resulted in VT termination in most cases. Interestingly, computational studies have suggested that spiral waves driving arrhythmias are more likely to approach the apex of the ventricle rather than the base due to the apex’s elliptic shape and high degree of anisotropy. One of the possible underlying mechanisms of local optogenetic VT cardioversion, as demonstrated in this study, might therefore be based on forcing the spiral wave away from the apex towards myocardial regions that favour critical wavefront collisions and subsequent arrhythmia termination. Future dedicated studies are needed to explore this finding in detail as it could lead to more refined optical termination protocols and perhaps a better understanding of anti-arrhythmic mechanisms in general.

Since myocardial light penetration is wavelength-dependent and paramount for effective optogenetic VT termination, we have studied the electrophysiological responses of ReaChR-expressing cells by whole-cell patch clamp experiments and also by sharp electrode measurements on myocardial tissue from TAC hearts. These experiments were complemented with in silico studies to simulate light penetration in the rat ventricular wall using a Monte Carlo-based method. The findings of these studies are in agreement with the computational modelling experiments of Karathanos et al., showing that optogenetic defibrillation of the human heart was feasible only when red excitation light was used. Now that the field of optogenetics is maturing into a potential candidate for next generation therapeutics, considerable progress is being made in the development of (i) channelrhodopsins with improved characteristics and (ii) deep in vivo light delivery. Such progress includes the
development of channelrhodopsins with enhanced light sensitivity and injectable nanoparticles emitting blue light after excitation with tissue-penetrating near-infrared light, which allows optogenetic activation of tissue with large dimensions, e.g. the human-sized heart. In addition, a recent computational study by Hussaini et al. demonstrated spiral wave termination in optogenetically modified cardiac tissue by so-called sub-threshold illumination, i.e. by using light intensities too low to evoke an action potential. This finding suggests that smart energy-saving
illumination protocols may suffice to optogenetically terminate cardiac arrhythmic activity under certain conditions. Future in vivo studies should reveal which combination of channelrhodopsin, light source and illumination strategy is best suited for termination of a particular type of arrhythmia in a particular pathological substrate. The outcome of such studies could contribute to the design and application of fully implantable optoelectronic devices in favour of optimal efficacy and safety.

In terms of safety, we have measured a maximum temperature at the surface of the LED device of ~41°C upon consecutive LED activation during thermal response experiments. This value can be considered harmless especially given the very short exposure to this peak temperature. It is important to note that this temperature was measured without the heart attached. Under in vivo conditions, the blood-perfused myocardium would act as a biological heatsink, thereby lowering the peak temperature of the LED device. Moreover, optical mapping and sharp electrode experiments of the cardiac apex showed that frequent and repetitive LED exposure during in vivo and ex vivo experiments did not cause significant abnormalities in wave propagation and electrical excitability. If needed, safety can be further improved by changing the design and materials of the cardiac light sources to reduce the thermal response, which should ideally be explored in future studies in large animal models.

The development of shock-free anti-arrhythmic device treatment for VTs is a much sought-after goal in cardiovascular research and therapy. In the USA alone, a large and growing number of ICDs are implanted annually to protect patients from potentially life-threatening VTs. While these devices have shown to improve survival in different subsets of patients, they are also known to cause long-lasting adverse effects on quality of life among those who have experienced shocks, especially when delivered inappropriately.6 Shock-free cardioversion of VTs, as potentially provided by cardiac optogenetics, may overcome the adverse effects of conventional ICDs as it would render the use of electric shocks for VT termination obsolete. This could not only increase the quality of life of ICD patients, but potentially even improve the prognosis as ICD shocks can cause direct myocardial injury.28

Several important steps have to be taken before optogenetic cardioversion therapy for VTs can be clinically studied. In essence, two important components need to be in place in order to enable optogenetic arrhythmia termination, namely (i) sufficiently high and widespread expression of opsins in the myocardium and (ii) activation of these opsins by adequate cardiac light delivery. While widespread cardiac transgene expression in large animal studies and human clinical trials is difficult to achieve, robust local transgene expression could be obtained by gene delivery methods, such as epicardial gene painting or by intramyocardial injections.29,30 For example, in this study, ReaChR was expressed via minimal invasive thoracic surgery or by percutaneous light fibre implantation into the myocardium.34 The latter approach has the advantage that all light is directly delivered to the myocardial wall, thereby maximizing illumination efficiency. In addition, when inserted mid-myocardially, the maximum distance between the light source and the opposite myocardial boundaries is minimized resulting in maximal light exposure of the ventricular wall. Future studies in larger animal models should focus on the potential short- and long-term effects of epicardial LED implantation, especially on mechanical function. Possible impairment of contractile activity could be overcome by the development of devices specifically designed for cardiac optogenetic purposes that take cardiac mechanical properties into account.33,35,36 For these thin, stretchable, and biocompatible devices, the best suited anatomical site for implantation within the thorax should be identified through rigorous investigation focusing on the optimal efficacy and safety of this intervention.

In our study, the cardiac substrate for VT was a hypertrophic cardiomyopathy model exhibiting signs of structural and electrical remodelling. Although this model has been a solid starting point for evaluating optogenetic VT termination in the remodelled heart by an implantable LED device and local optogenetic targeting, from a translational perspective, it will be important to evaluate the applicability of this approach in other cardiac diseases as well, for example by applying (i) models of acute ischaemia, (ii) chronic infarction models with scar formation, and (iii) heart failure models not based on chronic pressure overload caused by TAC. Furthermore, since the computational light penetration simulations in our study did not take account for the (small) light sensitivity differences of ReaChR per wavelength, future studies are needed to determine the cardiac mass that is effectively excited upon optogenetic illumination by different-coloured light and how this relates to efficacy of optogenetic VT termination. In addition, since this study made use of male animals, future studies should also include female animals in order to investigate potential gender differences.

In summary, although more translational studies are required, our findings do provide important new insights into the translational potential of pain-free cardioversion therapy by optogenetics. This was done by demonstrating this approach in a pathologically relevant in vivo model of VT through implant-based local red-shifted light delivery.

Supplementary material

Supplementary material is available at Cardiovascular Research online.

Authors’ contributions

E.C.A.N., A.A.F.d.V., and D.A.P. conceived the study, interpreted results, and wrote the manuscript. E.C.A.N., M.S.F., T.v.d.H., and V.P. performed the whole-cell patch clamp and optical mapping studies. C.I.B. and A.A.F.d.V. designed and produced the LED device and performed the optical modelling studies. B.O. performed the whole-cell path clamp and sharp electrode measurements. C.I.B. and A.A.F.d.V. designed and produced AAVVs. K.Z., M.J.S., T.J.v.B., and A.A.R. helped in interpreting the data. All authors refined the manuscript.

Acknowledgements

We would like to thank Roman Koning and Ronald Limpens (Department of Cell and Chemical Biology, LUMC) for producing the electron microscopic images and Minka Bax (Department of Cardiology, LUMC) for excellent assistance during animal experiments.

Funding

This study was supported by European Research Council (Starting grant 716509 to D.A.P.). Additional support was provided by the Netherlands Organization for Scientific Research (Vidi grant 91714336 to D.A.P.).
Conflict of interest: none declared.

Data availability

The data underlying this article are available in the article and in its Supplementary material online.

References

1. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SM, Hlatky MA, Jaglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2018;15:e190–e252.

2. John RM, Tedrow UB, Kaplan BA, Albert CM, Epstein LM, Sweeney MO, Miller AL, Michael GF, Stevenson WG. Ventricular arrhythmias and sudden cardiac death. Lancet 2012;380:1520–1529.

3. Roberts-Thomson KC, Lau DH, Sanders P. The diagnosis and management of ventricular tachyarrhythmias. Nat Rev Cardiol 2011;8:311–321.

4. Bradfield JS, Ajoida OA, Vasighi M, Shikvikumar K. Mechanisms and management of refractory ventricular arrhythmias in the age of autonomic modulation. Heart Rhythm 2018;15:1252–1260.

5. Josephson M, Wellens HJ. Implantable defibrillators and sudden cardiac death. Circulation 2004;109:2685–2691.

6. Magyar-Russell G, Thoms BD, Cai JX, Baveja T, Kuhl EA, Singh PP, Montenegro Michaud GF, Stevenson WG. Ventricular arrhythmias and sudden cardiac death. J Am Coll Cardiol 2016;68:223–231.

7. Deisseroth K. Optogenetics. Nat Methods 2011;8:26–29.

8. Nussinovitch U, Geppstein L. Optogenetics for in vivo cardiac pacing and resynchronisation therapies. Nat Biotechnol 2015;33:750–754.

9. Bruegmann T, Boyle PM, Vogt CC, Karathanos TV, Arevalo HJ, Fleischmann BK, Trayanova NA, Sasse P. Optogenetic defibrillation terminates ventricular arrhythmia in mouse hearts and human simulations. J Clin Invest 2016;126:3894–3904.

10. Vogt CC, Bruegmann T, Malan D, Oetersbach A, Roell W, Fleischmann BK, Sasse P. Systemic gene transfer enables optogenetic pacing of mouse hearts. Cardiovasc Res 2015;106:338–343.

11. Crocini C, Ferrantini C, Crippini R, Scardigli M, Yan P, Loew LM, Smith G, Cerbai E, Pravdin S, Dierckx H, Markhasin VS, Panfilov AV. Drift of scroll wave filaments in an optogenetically modified myocardium. J Physiol 2020;264–270.

12. Liu Z, Jia J, Rajeswaran J, Amin K, Uderwood MM, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2018;15:e190–e252.

13. Del Monte F, Butler K, Boecker W, Gwathmey JK, Hajjar RJ. Novel technique of aortic banding followed by gene transfer during hypertrophy and heart failure. Phys Genomics 2002;9:49–56.

14. Lin JY, Knutsen PM, Muller A, Kienfeld D, Tien SY. ReaChR: a red-shifted variant of channelrhodopsin enables deep transcranial optogenetic excitation. Nat Neurosci 2013;16:1499–1508.

15. Pravdin S, Dierckx H, Markhasin VS, Panfilov AV. Drift of scroll wave filaments in an optogenetically modified myocardium. J Physiol 2020;264–270.

16. Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys 1984;10:787–800.

17. Tian Z, Nan Q, Nie X, Dong T, Wang R. The comparison of lesion outcome and temperature field determined by different ways in atrial radiofrequency ablation. Biomed Eng Online 2016;15:124.

18. Quinones Urbe RA, Luther S, Diaz-Maué L, Richter C. Energy-reduced arrhythmia termination using global photostimulation in optogenetic murine hearts. Front Physiol 2018;9:1651.

19. deAlmeida AC, van Oort RJ, Wehrens XR. Transverse aortic constriction in mice. J Vis Exp 2010;38:1729.

20. Xia Y, Lee K, Li N, Corbett D, Mendosa L, Frangogiannis NG. Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochim Cell Biol 2009;131:471–481.

21. Cheng Y, Li H, Wang L, Li J, Kang W, Rao P, Zhou F, Wang X, Huang C. Optogenetic approaches for termination of ventricular tachyarrhythmias after myocardial infarction in rats. J Biphotosci 2020;10:e202000003.

22. Li J, Wang L, Luo J, Li H, Rao P, Cheng Y, Wang X, Huang C. Optogenetic and photoablation in rats with time-course induced myocardial fibrosis 1 year after a single intravenous injection of adeno-associated virus channelrhodopsin-2. Heart Rhythm 2020;18:109–117.

23. Karathanos TV, Bayer JD, Wang D, Boyle PM, Trayanova NA. Opsin spectral sensitivity determines the effectiveness of optogenetic termination of ventricular fibrillation in the human heart: a simulation study. J Physiol 2016;594:6879–6891.

24. Rajasepathy P, Sankaran S, Marshall JH, Kim CK, Ferenczi E, Lee SY, Berndt A, Ramakrishnan C, Jaffe A, Al M, Lipton C, Deusseroth K. Projections from neocortex mediate top-down control of memory retrieval. Nature 2015;526:653–659.

25. Chen S, Weitmer TM, Zeng X, He L, Wang L, Yao T, Huang AJF, HashimotoDari Y, Kano M, Iwasaki H, Parajuli OK, Okabe S, Teh D, Ali AH, Tsutsumi-Kimura I, Tanaka KF, Liu X, McHugh TJ. Near-infrared deep brain stimulation via upconversion nanoparticle-mediated optogenetics. Science 2018;359:679–684.

26. Kim S, Kyung T, Chung JH, Kim N, Keun M, Lee J, Park H, Kim HM, Lee S, Shin HS, Do Heo W. Non-invasive optical control of endogenous Ca(2+)-channels in awake mice. Nat Commun 2020;11:2020.

27. Pravdin S, Dierckx H, Markhasin VS, Panfilov AV. Drift of scroll wave filaments in an optogenetically modified myocardium. J Physiol 2020;264–270.

28. Sham’s RA, Nery P, Sadek M, Yung D, Redpath C, Perrin M, Sarak B, Birnie D. Myocardial injury secondary to ICD shocks: insights from patients with lead fracture. J Clin Electrophysiol 2018;32:223–241.

29. Kitsuki K, McDonald AD, Asano T, Donahue JK. Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer. Circulation 2005;111:264–270.

30. Liu Z, Jia J, Rajeswaran J, Amin K, Uderwood MM, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2018;15:e190–e252.

31. Gabisonia K, Prosdocimo G, Aquaro GD, Carlucci L, Zentilin L, Secco I, Ali H, Braga L, Gorgodze N, Bernini F, Burchelli S, Collesi C, Zandonà S, Sinagra G, Piacent M, Zachchigna S, Bussani R, Recchia FA, Giacca M. MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs. Nature 2019;569:418–422.

32. Kim RH, Kim DH, Xiao J, Kim BH, Park SI, Panilaitis B, Ghaffari R, Yao J, Li M, Liu Z, Malayarchuk V, Kim DG, Le AP, Nuzzo RG, Kaplan DL, Omeneto FG, Huang Y, Kang Z, Rogers JA. Waterproof AlInGaP optoelectronics on stretchable substrates with applications in biomedicine and robotics. Adv Mater 2021;33:1–16.

33. Park SL, Brenner DS, Shin G, Morgan CD, Copits BA, Chung HU, Pullem Y, Noh KN, Davidson S, Oh SJ, Yoon J, Kang KI, Saminieri VK, Norman M, Grajales-Reyes JG, Vogt SK, Sundram SS, Wilson KM, Ha JS, Xu R, Pan T, Kim TI, Huang Y, Montana MC, Golden JP, Bruchas MR, Gerace RW, Rogers JA. Soft, stretchable, fully implantable miniaturized optoelectronic systems for wireless optogenetics. Nat Biotechnol 2015;33:1280–1286.

34. Zegers-Johnston CM, Ayub S, Fernandez MC, Rog-Zielinska EA, Barz F, Paul O, Kohl P, Rath P. Cardiac pacing using transmural multi-LED probes in channelrhodopsin-expressing mouse hearts. Poo Biphys Mol Biol 2020;1:541–541.

35. Xu L, Gutbrod SR, Ma Y, Petrossiana A, Liu Y, Webb RC, Fan JA, Yang Z, Xu R, Whalen JI, Weiland JD, Huang Y, Efrem IR, Rogers JA. Materials and fractal designs for 3D multifunctional integumentary membranes with capabilities in cardiac electrotherapy. Adv Mater 2015;27:1731–1737.

36. Fang H, Zhao J, Yu KJ, Song E, Farimani AB, Chiang CH, Jin X, Xue Y, Xu D, Du W, Sene S, Zhong Y, Yang Z, Feng G, Choi SW, Chauhduri S, Huang Y, Alam MA, Virent J, Alku NR, Rogers JA. Ultrathin, transferred layers of thermally grown silicon dioxide as biofluid barriers for ioncheapable integrated electronic systems. Proc Natl Acad Sci USA 2016;113:11682–11687.